This research offers the impervious perception that CRISPR/Cas9-intermediated incorporation of an AGXT minigene into the AAVS1 safe harbor locus in patient-precise iPSCs is an effective way to produce functionally rectified hepatic cells, which in future explorations may assist as a source for autologous cell-based gene therapy for the medication of PH1. This evidence concerns the gene AGXT and primary hyperoxaluria type 1.